

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 38/13, 9/20, 47/20	A1	(11) International Publication Number: WO 99/13900 (43) International Publication Date: 25 March 1999 (25.03.99)
(21) International Application Number: PCT/CA98/00880 (22) International Filing Date: 16 September 1998 (16.09.98) (30) Priority Data: 328751 16 September 1997 (16.09.97) NZ (71)(72) Applicant and Inventor: SHERMAN, Bernard, Charles [CA/CA]; 50 Old Colony Road, Willowdale, Ontario M2L 2K1 (CA).		(81) Designated States: AU, BR, BY, CA, CN, CZ, HU, ID, IL, JP, KR, MX, NO, PL, RU, SG, SI, TR, UA, US, YU, European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). Published <i>With international search report.</i>
(54) Title: SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLOSPORIN AND AN ANIONIC SURFACTANT (57) Abstract A solid pharmaceutical composition for oral administration comprising a cyclosporin and an anionic surfactant, preferably sodium lauryl sulfate.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

SOLID PHARMACEUTICAL COMPOSITIONS COMPRISING A CYCLOSPORIN AND AN ANIONIC SURFACTANT

TECHNICAL FIELD

5

Solid pharmaceutical compositions for oral administration of cyclosporins.

BACKGROUND ART

10

The term "cyclosporin" as used herein refers to any member of a class of nonpolar polypeptides, as defined in the Merck Index, Twelfth Edition. One such cyclosporin is cyclosporin A, also known as "cyclosporine" and hereinafter referred to as "cyclosporine", known to be therapeutically active as an immunosuppressant.

15

Cyclosporins are hydrophobic and have low solubility in aqueous media. This makes it difficult to design pharmaceutical compositions (i.e. dosage forms) comprising cyclosporins which exhibit satisfactory absorption into systemic circulation after oral administration.

20

The cyclosporin can be dissolved in an organic solvent (e.g. ethanol or propylene glycol), but, if the solvent is water-miscible, when the composition is mixed with gastrointestinal fluid or other aqueous medium, the cyclosporin will precipitate.

25

Methods of overcoming this problem are known in the prior art. The most common approach is to dissolve the cyclosporin in a solvent system that comprises at least one lipophilic (hydrophobic) solvent and a surfactant, so that the composition disperses into an emulsion when mixed into gastrointestinal fluid or other aqueous medium.

30

Such compositions are called "emulsion preconcentrates".

U.S. patent 4388307 discloses such compositions. A commercial product that has been sold under the trademark Sandimmune (registered trademark) is made according to U.S. patent 4388307, and, more specifically, comprises
5 cyclosporine dissolved in a solvent system comprising ethanol as hydrophilic solvent, a vegetable oil as lipophilic solvent, and a surfactant. The ethanol is required to dissolve the cyclosporine in the composition, as the vegetable oil has inadequate capacity to dissolve cyclosporins.

10 Sandimmune (registered trademark) is sold in the form of both an oral liquid, which is an emulsion preconcentrate intended to be diluted into an aqueous drink before ingestion, and a soft gelatin capsule containing the emulsion preconcentrate.

15 U.S. patent 5342625 discloses compositions that are superior in certain respects to the compositions taught in U.S. patent 4388307. The compositions of U.S. patent 5342625 again comprise, cyclosporine, a hydrophilic solvent, a lipophilic (i.e. hydrophobic) solvent and a surfactant. The hydrophilic solvent is either propylene glycol or an alkyl or tetrahydrofurfuryl di- or partial-ether of a low
20 molecular weight mono- or poly-oxy-alkanediol.

Compositions according to U.S. patent 5342625, when added to water, disperse into emulsions with droplet size of less than 2000Å, which is smaller than those obtained with prior art compositions, thus leading to improved absorption.

25

Emulsions with droplet size of less than 2000Å are defined as "microemulsions". Compositions that, upon addition to water, disperse into microemulsions are called "microemulsion preconcentrates".

30

5 A composition made according to the disclosure of U.S. patent 5342625 is now marketed under the trademark Neoral (registered trademark). As is the case with Sandimmune (registered trademark), Neoral (registered trademark) is available as both an oral liquid and soft gelatin capsules.

10 For both the soft gelatin capsules and the oral liquid, Neoral (registered trademark) microemulsion preconcentrate comprises cyclosporine dissolved in ethanol and propylene glycol as hydrophilic solvents, corn oil glycerides as lipophilic solvent, and polyoxyl 40 hydrogenated castor oil as surfactant. It also contains dl-alpha-tocopherol at a level of about one percent by weight as antioxidant.

15 For both Sandimmune (registered trademark) and Neoral (registered trademark), the capsule formulations have certain undesirable features.

Specifically:

20 1. They both contain ethanol, which is volatile. This means that the capsules must be individually packaged in metal pouches to avoid evaporation of the ethanol.

25 2. The capsules are relatively large and difficult to swallow. This is because the formulations must contain substantial quantities of the hydrophilic and lipophilic solvents, which are needed to keep the cyclosporine and surfactant in solution. The total weight of contents of each capsule is about ten times the weight of the cyclosporine contained therein.

30 The prior art discloses some attempts to overcome these problems by use of formulations that contain the cyclosporin and surfactant, but no solvent.

Such compositions are solid in form and can be used to make tablets or as a fill for two-piece hard gelatin capsules.

5 Japanese patent No. 2536876 of Takada et al discloses powdery preparations comprising a cyclosporin dispersed in a solid, non-surfactant carrier together with a surfactant. All of the examples in this patent use as the surfactant polyoxyethylene hydrogenated castor oil, which is non-ionic. In the examples, the total weight of the compositions is from 5 to 151 times the weight of the
10 cyclosporin, and it appears unlikely that any of the disclosed compositions, particularly those with smaller amounts of the inactive ingredients, would give absorption in humans equivalent to that of Sandimmune (registered trademark) or Neoral (registered trademark).

15 European Application No. 88305138.5 (publication No. 0294239) of Kurihara and Murano discloses solid compositions comprising a cyclosporin in admixture with an amount of alpha-cyclodextrin or a functional derivative thereof sufficient to solubilize the cyclosporin in water. However, the amount of alpha-cyclodextrin required is generally many times the amount of cyclosporin by weight, so that
20 this approach appears incapable of providing dosage forms smaller than Sandimmune (registered trademark) or Neoral (registered trademark) capsules. Additionally, there is no indication that any of the disclosed compositions will, upon oral administration, give absorption equivalent to that of Sandimmune (registered trademark) or Neoral (registered trademark).

25 In Pharmaceutical Research, Vol. 8, No. 4, 1991, pp 518-522, Abdallah and Mayersohn disclose a tablet containing cyclosporine 100 mg, mannitol 250 mg, microcrystalline cellulose 200 mg, stearic acid 20 mg, and sodium dodecyl sulfate 10 mg. It is stated that the tablets gave absorption comparable to that
30 of Sandimmune (registered trademark) in a comparative bioavailability study in dogs.

However, the relatively large amount of inactive ingredients used precludes tablets or capsules significantly smaller than Sandimmune (registered trademark) or Neoral (registered trademark), and there is no evidence given that such a
5 formulation would give absorption equivalent to that of Sandimmune or Neoral in humans.

In view of the problems with prior art formulations, it is the object of the present invention to enable pharmaceutical compositions containing a cyclosporin (and
10 in particular cyclosporine) with the following properties:

1. They are solid at room temperature and free of volatile solvents.
- 15 2. Upon oral administration, they enable absorption comparable to that of Sandimmune (registered trademark) or Neoral (registered trademark).
- 20 3. They enable capsules or tablets of smaller size than Sandimmune (registered trademark) and Neoral (registered trademark). That is to say, they enable compositions wherein the content of the cyclosporin by weight exceeds ten percent and preferably twenty percent of the weight of the composition.

BRIEF SUMMARY OF THE INVENTION

25 It has surprisingly been found that the objects of the invention can be achieved by a pharmaceutical composition comprising a cyclosporin in admixture with an anionic surfactant, wherein the amount of anionic surfactant is at least about forty percent of the minimum quantity that would be needed to dissolve the cyclosporin in water, using a quantity of water small enough that the
30 concentration of the anionic surfactant in the water would exceed the critical micelle concentration.

DETAILED DESCRIPTION OF THE INVENTION

5 Anionic surfactants usable within the scope of the invention will include any anionic surfactant that is solid at normal room temperature (20°C to 25°C) and of sufficiently low toxicity that it is acceptable for oral administration in a pharmaceutical product.

10 The most commonly used anionic surfactants are those containing carboxylate, sulfonate, and sulfate ions.

Preferred anionic surfactants are sodium-alkyl sulfates and sulfonates, and sodium alkyl aryl sulfonates.

15 Most preferred is sodium lauryl sulfate (also known as sodium dodecyl sulfate), which is widely used as an emulsifier and solubilizer in pharmaceutical products.

20 The ability of anionic surfactants to solubilize cyclosporins in water substantially increases when the concentration of the surfactant in water substantially exceeds the critical micelle concentration.

Using sodium lauryl sulfate, for example, the critical micelle concentration is about 0.1% by weight.

25 At concentrations of sodium lauryl sulfate in water under 0.1%, the amount of cyclosporine that will dissolve is less than 50% by weight of the amount of sodium lauryl sulfate dissolved, but at concentrations of sodium lauryl sulfate in water of 1% or more, the amount of cyclosporine that will dissolve is about equal
30 by weight to the amount of sodium lauryl sulfate dissolved.

As aforesaid, compositions with the scope of the invention are compositions wherein the quantity of anionic surfactant is at least about forty percent of the minimum quantity that would be needed to dissolve the cyclosporin in water, using a quantity of water small enough that the concentration of the anionic surfactant in the water would exceed the critical micelle concentration.

Using cyclosporine and sodium lauryl sulfate, for example, it follows that compositions within the scope of the invention would be compositions wherein the amount of sodium lauryl sulfate is at least about forty percent by weight of the amount of cyclosporine. The amount of sodium lauryl sulfate will preferably be at least about eighty percent by weight of the amount of cyclosporine.

Because of toxicity concerns, the amount of anionic surfactant should not exceed that which is needed to enable satisfactory absorption of the drug upon oral administration.

The amount of anionic surfactant will preferably not exceed about four times the minimum quantity that would be needed to dissolve the cyclosporin in water, again using a quantity of water small enough that the concentration of the surfactant in the water would exceed the critical micelle concentration.

It follows, for example, that in the case of compositions comprising cyclosporine and sodium lauryl sulfate, the amount of sodium lauryl sulfate by weight preferably will not exceed four times the amount of cyclosporine. Most preferably it will not exceed three times the amount of cyclosporine.

To enable small capsules or tablets, the cyclosporin will preferably comprise at least ten percent, and most preferably at least twenty percent, of the composition by weight.

5 Compositions within the scope of the invention can be made by mixing the cyclosporin and anionic surfactant, optionally with other ingredients, in dry form and then further processing the mixed powder into tablets or filling the mixed powder into empty two-piece hard gelatin capsules.

10 However, the effectiveness of the surfactant is increased and the amount needed is to achieve adequate absorption of the drug is thus decreased, if, in the process of manufacture of the composition, the cyclosporin and the anionic surfactant are dissolved together (optionally along with other ingredients) in a solvent or a solvent system, and the solvent or solvents are then evaporated to give a dry co-precipitate of the cyclosporin and anionic surfactant.

15 The evaporation of the solvent or solvents will preferably be done by spray-drying or freeze-drying, most preferably by spray-drying.

20 In cases in which the amount of anionic surfactant being used is sufficient to fully dissolve the cyclosporin in water, water can be used as the sole solvent. If the amount of surfactant is less than needed to fully dissolve the surfactant in water, then the cyclosporin and surfactant can be dissolved in a solvent system comprising a mixture of water and an organic solvent, preferably a volatile alcohol such as methanol.

25 The invention will be further illustrated by the following examples, which are intended to be illustrative but not limiting of the scope of the invention.

EXAMPLE 1

30 50.0 g of cyclosporine, 55.0 g of sodium lauryl sulfate, and 40.0 g lactose monohydrate were mixed together in dry form.

The mixed powder was filled into size 2 capsules at a net fill weight of 290 mg per capsule. Each capsule thus contained 100 mg of cyclosporine, 110 mg of sodium lauryl sulfate and 80 mg of lactose monohydrate.

5

EXAMPLE 2

200.0 g of cyclosporine, 220.0 g of sodium lauryl sulfate, and 160.0 g of mannitol were dissolved together in 2000.0 g of water. The solution was then spray-dried.

10

The spray-dried powder was then compacted, and then ground into granules. The granules were then filled into size 2 capsules at a net fill weight of 290 mg per capsule. Each capsule thus contained 100 mg of cyclosporine, 110 mg of sodium lauryl sulfate, and 80 mg of mannitol.

15

EXAMPLE 3

200.0 g of cyclosporine, 440.0 g of sodium lauryl sulfate and 160.0 g of mannitol were dissolved together in 2000.0 g of water. The solution was then spray-dried.

20

The spray-dried powder was then compacted, and then ground into granules. The granules were then filled into size 1 capsules at a net fill weight of 400 mg per capsule. Each capsule thus contained 100 mg of cyclosporine, 220 mg of sodium lauryl sulfate, and 80 mg of mannitol.

25

EXAMPLE 4

500.0 g of cyclosporine and 1200.0 g of sodium lauryl sulfate were dissolved together in 5500 g of water. The solution was then spray-dried. The spray-dried powder was then compacted, and then ground into granules. The granules were then filled into size 1 capsules at a net fill weight of 340 mg per capsule. Each capsule then contained 100 mg of cyclosporine and 240 mg of sodium lauryl sulfate.

30

EXAMPLE 5

500.0 g of cyclosporine and 400.0 g of sodium lauryl sulfates were dissolved
together in a mixture of water and methanol. The solution was then spray-dried.
The spray-dried powder was then compacted, and then ground into granules.
The granules were then filled into size 3 capsules at a net fill weight of 180 mg
per capsule. Each capsule thus contained 100 mg of cyclosporine and 80 mg
of sodium lauryl sulfate.

COMPARATIVE BIOAVAILABILITY STUDIES

A 3-way comparative bioavailability study was done in 6 human volunteers to
compare the absorption of the capsules of example 1 and the capsules of
example 2 to Sandimmune (registered trademark) capsules 100 mg. Over a
period of 72 hours from ingestion, the mean extent of the absorption was found
to be 96% of that of Sandimmune (registered trademark) for the capsules of
example 1 and 121% of that of Sandimmune (registered trademark) for the
capsules of example 2.

A 3-way comparative bioavailability study was done in 6 human volunteers to
compare the absorption of the capsules of example 2 and the capsules of
example 3 to Neoral (registered trademark) capsules 100 mg. Over a period of
72 hours from ingestion, the mean extent of absorption was found to be 73% of
that of Neoral (registered trademark) for the capsules of example 2 and 92% of
that of Neoral (registered trademark) for the capsules of example 3.

WHAT IS CLAIMED IS:

- 5 1. A solid pharmaceutical composition for oral administration comprising a cyclosporin and an anionic surfactant, wherein the amount of anionic surfactant is at least about forty percent of the minimum amount that would be needed to dissolve the cyclosporin in water using a quantity of water small enough that the concentration of the anionic surfactant in the water would exceed the critical micelle concentration.
- 10 2. A composition as in claim 1 wherein the amount of anionic surfactant is not more than about four times the minimum amount that would be needed to dissolve the cyclosporin in water using a quantity of water small enough that the concentration of the anionic surfactant in water
- 15 3. A composition as in claim 1 or 2 wherein the anionic surfactant is selected from sodium alkyl sulfates, sodium alkyl sulfonates and sodium alkyl aryl sulfonates.
- 20 4. A composition as in claim 1 or 2 wherein the anionic surfactant is sodium lauryl sulfate.
- 25 5. A solid pharmaceutical composition comprising a cyclosporin and sodium lauryl sulfate, wherein the amount of sodium lauryl sulfate by weight is from about 40% to about 400% of the amount of the cyclosporin.
- 30 6. A composition as in claim 5 wherein the amount of sodium lauryl sulfate by weight is from about 80% to about 300% of the amount of the cyclosporin.

- 5
7. A composition as in any of claims 1 to 6, wherein the cyclosporin comprises more than ten percent of the composition by weight.
8. A composition as in any of claims 1 to 6, wherein the cyclosporin comprises more than twenty percent of the composition by weight.
- 10
9. A composition as in any of claims 1 to 6, wherein the cyclosporin is cyclosporine.
10. A composition as in any of claims 1 to 9 contained within a 2-piece hard gelatin capsule.
- 15
11. A composition as in any of claims 1 to 9 in the form of a tablet.
12. A process of making a composition as in any of claims 1 to 9 comprising the steps of dissolving the cyclosporin and anionic surfactant in a solvent or a combination of solvents and then evaporating the solvent or solvents.
- 20
13. A process as in claim 12 wherein water is used as solvent.
14. A process as in claim 12 or 13 wherein the evaporation is done by spray-drying.
- 25

25

30

INTERNATIONAL SEARCH REPORT

Internat. Application No.

PCT/CA 98/00880

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 A61K38/13 A61K9/20 A61K47/20

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	PATENT ABSTRACTS OF JAPAN vol. 017, no. 436 (C-1096), 12 August 1993 & JP 05 097697 A (LION CORP), 20 April 1993 see abstract	1-5
P, X	--- PATENT ABSTRACTS OF JAPAN vol. 098, no. 008, 30 June 1998 & JP 10 059862 A (MEIJI SEIKA KAISHA LTD), 3 March 1998 see abstract	1-9
X	--- WO 96 25150 A (NANOSYSTEMS LLC) 22 August 1996 see claims 21,26 --- -/-	1-4

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

18 December 1998

Date of mailing of the international search report

29/12/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax: (+31-70) 340-3016

Authorized officer

Fischer, W

INTERNATIONAL SEARCH REPORT

Internat I Application No

PCT/CA 98/00880

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DD 298 351 A (JENAPHARM GMBH) 20 February 1992 see the whole document ---	1-4, 7-10
X	DE 40 03 844 A (SANDOZ AG) 16 August 1990 see the whole document ---	1-4, 7-11
X	WO 97 02017 A (ELAN CORP PLC ;CLANCY MAURICE JOSEPH ANTHONY (IE); CUMMING KENNETH) 23 January 1997 see the whole document see claims 3,4 ---	1-4
A	US 5 652 212 A (CAVANAK THOMAS ET AL) 29 July 1997 ---	
A	US 5 641 745 A (RAMTOOLA ZEIBUN) 24 June 1997 -----	

INTERNATIONAL SEARCH REPORT

Information on patent family members

Internat Application No

PCT/CA 98/00880

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
WO 9625150	A	22-08-1996	US	5573783 A	12-11-1996
			AU	4866996 A	04-09-1996
			CA	2212803 A	22-08-1996
			EP	0812187 A	17-12-1997

DD 298351	A	20-02-1992	NONE		

DE 4003844	A	16-08-1990	AT	27290 A	15-05-1998
			AU	630413 B	29-10-1992
			AU	4925290 A	16-08-1990
			BE	1003009 A	22-10-1991
			CA	2009533 A	09-08-1990
			CH	679277 A	31-01-1992
			CY	1903 A	22-11-1996
			DK	32790 A	10-08-1990
			FI	97524 B	30-09-1996
			FR	2642650 A	10-08-1990
			GB	2230440 A,B	24-10-1990
			GR	90100076 A,B	28-06-1991
			HK	37296 A	15-03-1996
			HU	213394 B	30-06-1997
			IL	93298 A	10-06-1997
			IT	1240758 B	17-12-1993
			JP	2235817 A	18-09-1990
			LU	87675 A	08-10-1991
			NL	9000299 A	03-09-1990
			NO	301576 B	17-11-1997
			PT	93079 A,B	31-08-1990
			SE	9000441 A	08-08-1991
			US	5756450 A	26-05-1998
			IE	65191 B	04-10-1995

WO 9702017	A	23-01-1997	IE	80467 B	29-07-1998
			AU	6239496 A	05-02-1997
			CA	2226008 A	23-01-1997
			CZ	9704134 A	15-04-1998
			EP	0836475 A	22-04-1998
			NO	975872 A	03-03-1998
			SK	175997 A	03-06-1998

US 5652212	A	29-07-1997	US	5639724 A	17-06-1997
			BE	1005236 A	08-06-1993
			CH	680650 A	15-10-1992
			CY	1886 A	05-04-1996
			DE	4005190 A	23-08-1990
			FR	2643262 A	24-08-1990
			GB	2228198 A,B	22-08-1990
			HK	149595 A	29-09-1995
			IT	1240765 B	17-12-1993
			JP	1888154 C	07-12-1994
			JP	2255623 A	16-10-1990
			JP	6011703 B	16-02-1997
			US	5759997 A	02-06-1998

US 5641745	A	24-06-1997	IE	950233 A	16-10-1996
			AU	5286696 A	23-10-1996
			CA	2217462 A	10-10-1996
			EP	0818996 A	21-01-1998

Information on patent family members

PCT/CA 98/00880

Form PCT/ISA/210 (patent family annex) (July 1992)